LAURUS Labs
Chemistry for Better Living

July 24, 2026

To	To
The Corporate Relations Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 **Code: 540222**	**The Listing Department** **National Stock Exchange of India Ltd.,** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 **Code: LAURUSLABS**

Dear Sir / Madam,

Sub: Investors / Analysts Presentation

Please find enclosed the presentation to the Investors / Analysts on the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2026, for the Investors / Analysts call scheduled on July 24, 2026 at 05.00 p.m. (IST), which was already intimated on July 09, 2026.

The presentation is also being uploaded on the website of the Company i.e., www.lauruslabs.com.

This is for your information and records.

Thanking you,

Yours sincerely,
For **Laurus Labs Limited**

VENKATESWAR REDDY GOGIREDDY
Digitally signed by VENKATESWAR REDDY GOGIREDDY
Date: 2026.07.24 14:54:21 +05'30'

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Registered Office
Laurus Labs Limited
Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.
T +91 891 682 1101, 1102, **F** +91 891 682 1103
E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office
Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.
T +91 40 6659 4333
F +91 40 6659 4320
CIN : L24239AP2005PLC047518

LAURUS Labs
Chemistry for Better Living

Q1-FY 2027 Financial Results

24/07/2026

Agenda

1 Q1 - FY 2027 Corporate Overview

2 Q1 - FY 2027 Financial Overview

3 Q1 - FY 2027 Business Review & Strategy

LAURUS Labs
Chemistry for Better Living

Safe Harbor Statement

This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise.

This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same.

1

Corporate Overview

Q1 - FY 2027

Executive Summary

- Continued strong Q1 performance ; ₹ 2,026 Cr Revenue with 29% growth
- Strong growth in CDMO revenue driven by commercial projects supplies and steady momentum in Affordable Medicines segment
- ₹ 644 Cr EBITDA with margins of 31.8%, increased by 7.0% pts, contributed by enhanced CDMO revenue and operational leverage
- Gross margins expansion of over 3.3% pts to 62.7% on healthy business segment mix
- Continued investment into manufacturing network expansion and niche capabilities with overall CAPEX at 19% of sales

Continue to drive Growth CAPEX projects across portfolio and technologies

- >85% Growth CAPEX; Building diversified portfolio across technologies
- Healthy order book, internal pipeline and key Customers
- Key projects in API, Formulations, Peptides, Fermentation, Gene Therapy and Antibody Drug Conjugates
- Q1 CAPEX at ₹ 394 Cr; 19% of Revenue
- ATR improving in medium-term in-line with 5 year Long term average

Q1 CAPEX : ₹394 Cr

(19% of Revenue)



FY22-27* CAPEX : ₹4700+ Cr

(16% of Revenue)



ATR progress (FY22-27*)



* Cumulative addition including CWIP, Land, ETP and plant maintenance till June 2027

LAURUS Labs
Chemistry for Better Living

Strengthening Integrated manufacturing network & Capabilities to enable customers

Small Molecules API & FDF

Unit 1 & 3, Vizag **+3600 kL**

Unit 5, Vizag **161 kL**

- Unit 7, Vizag *(new site)*
- Unit 2, Vizag **+12bn units**
- Unit 4, Vizag **+2000 kL**

Unit 6, Vizag **1476 kL**

- Unit 10, Vizag *(new site)*
- LSPL 2, Vizag **+400 kL**

LSPL 4, Vizag **+300 kL**

- KRKA JV site, Hyderabad *(new site)*

R & D

R&D 1 & Kilo lab, Hyderabad

R&D 2, Hyderabad

Fermentation

LB-1 & LB-2, Bangalore **+240 kL**

- LB-4, Vizag **+400 kL**^ *(new site)*

CGT & ADC

CAR-T unit-1, Mumbai **+600 treatment**

CAR-T unit-2, Mumbai **+2500 treatment**

- Gene Therapy/ADC, Hyderabad

Enabling Technology Platforms

- High potent
- Flow technology
- Continuous manufacturing
- Peptides
- Bio-catalysis
- Trickle bed hydrogenation
- Spray Drying

6 Research & Development assets

15 Manufacturing assets

8300 kL	12 billion	240 kL	1570	56000 m^2
API capacity	FDF capacity	Fermentation capacity	Research Scientists	GLP lab facility

- Site under expansion or construction

^ Capacity proposed in Phase 1

LAURUS Labs
Chemistry for Better Living

Confirming SBTi targets and consistent ESG recognition

SBTi roadmap towards GHG reduction target 2031

Scope 1 + 2



Absolute reduction by 42% until FY31 (vs. FY25)

Scope 3



Intensity reduction per ₹ by 51.6% until FY31 (vs. FY25)

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

- >50% electricity from renewable source (Wind+Solar) by 2031 via PPA for all sites
- Near term GHG reduction target validated by SBTi
- Sustainable Procurement code inline with ISO 20400:2017 principles established

Key recognitions for our ESG programs

SILVER | Top 15%
ecovadis
Sustainability Rating
JUN 2026

Laurus Labs Limited
Pharmaceuticals
Sustainability Yearbook Member
Corporate Sustainability Assessment (CSA) 2025

MSCI ESG RATINGS
BBB
CCC | B | BB | BBB | A | AA | AAA

S&P Global ESG Score
81/100
Data Availability: Very High
Last updated: November 05, 2025

NATIONAL SAFETY COUNCIL OF INDIA
SAFETY AWARDS

UN GLOBAL COMPACT

Great Place To Work.
Certified
JUL 2025-JUL 2026
INDIA

LAURUS Labs
Chemistry for Better Living

2

Financial Overview

Q1 - FY 2027

1Q FY27: Highest Revenue, EBITDA and Profit momentum

1Q FY27 Financial Summary

[₹ Crore]	4Q FY26	1Q FY27	1Q FY26	*Y-o-Y*	*Q-o-Q*
Revenue	**1,812**	**2,026**	**1,570**	***29%***	***12%***
Gross Margins	*61.4%*	*62.7%*	*59.4%*	*+3.3%*	*+1.3%*
EBITDA	**523**	**644**	**389**	***66%***	***23%***
% to Revenue	*28.9%*	*31.8%*	*24.8%*	*+7.0%*	*+2.9%*
Net Profit	**279**	**368**	**163**	***+126%***	***+32%***
% to Revenue	*15.4%*	*18.2%*	*10.4%*	*+7.8%*	*+2.8%*
EPS (₹)	**5.2**	**6.8**	**3.0**	***+127%***	***+31%***

Comments

- Revenue : ₹ 2,026 Cr, increased 29% primarily driven by robust CDMO growth supported by sustained Affordable Medicine business (led by FDF)
- Gross Margins : 62.7%, increased by 330 bps on better divisional mix
- EBITDA : ₹ 644 Cr, increased by 66% Y/Y
- EBITDA Margins : 31.8%, increased 700 bps Y/Y, due to favorable product mix and improving operational leverage
- Net Profit : ₹ 368 Cr, increased 126% Y/Y
- R & D spends reported at ₹ 118 Cr* (5.8% of Revenue), increased by 74% due to development efforts toward building Advanced Biologics infrastructure

* Including Capex R&D spends of ₹ 35 Cr towards Advanced Biologics (Gene therapy and ADC)

LAURUS Labs
Chemistry for Better Living

1Q FY27: Driven by Solid CDMO performance

1Q FY27 Divisional Revenue Performance

[₹ Crore]	4Q FY26	1Q FY27	1Q FY26	*Y-o-Y*	*Q-o-Q*
CDMO	**589**	**870**	**522**	***67%***	***48%***
Small molecules	524	835	493	*69%*	*59%*
Bio	65	35	29	*21%*	*-46%*
Affordable Medicines (Generics)	**1,223**	**1,156**	**1,048**	***10%***	***-5%***
API	772	654	637	*3%*	*-15%*
FDF	451	502	411	*22%*	*11%*
Total Revenue	**1,812**	**2,026**	**1,570**	***29%***	***12%***
ARV Revenue*	683	669	647	*3%*	*-2%*

1Q FY27 Divisional Mix



* Includes API and Formulation (FDF) combined revenue

LAURUS Labs
Chemistry for Better Living

Quarterly Performance Summary: Sustained growth momentum

Revenue



EBITDA & Gross Profit Margins



RoCE (ttm EBIT/Capital Employed)



Net Leverage (Net Debt/ ttm EBITDA)



LAURUS Labs
Chemistry for Better Living

3

Business Review & Strategy

Q1 - FY 2027

CDMO – Small molecules: High quality execution, Continuous capacity expansion

Revenue Growth



Comments

- Strong business model driving continuous growth; +69% Y/Y, driven by steady progression of late-stage clinical projects and commercial API supplies
- Sustained business momentum across technologies and sites
- Continued focus on new modalities with key partners and fully integrated projects
- Expanding pipeline with over 125 active projects
- Continued to build large-scale capacities in small molecules API at Vizag. Further, advancing commercial scale peptides block based on customer demand

LAURUS Labs
Chemistry for Better Living

Bio – Healthy demand and pipeline progress

Revenue Growth



Comments

- Growth through revenue diversification continues; +21% Y/Y
- Healthy pipeline progress on high potential larger Global accounts across AOF and CDMO
- Strong traction in the enzymatic technology application across small molecule clinical and commercial API projects
- Fermentation manufacturing site (Vizag) >400kL planned capacity build up on track and capacity blocking by customers under discussion. Facility to be commissioned by 3QFY27

LAURUS Labs
Chemistry for Better Living

Affordable Medicines – Sustained momentum amid macro volatility

Revenue Growth



Global FDF filings	US	EU	Canada	ROW
Approved	37*	19	16	59
Pending	14	3	7	9
Total	**51**	**22**	**23**	**68**

* Includes 15 Tentative approvals in US

Comments

- Healthy order book, steady ARV and established product volume growth/new launches in US driving 10% growth
- Consistent deliveries track record amid continuing global supply chain challenges
- Most of the Capacity expansion/allocation going as per plan with focus on integrated CMO supplies
- Ramping product registration in EM markets. Further, opened new office in South Africa to strengthen business opportunity
- KRKA JV update: FDF site progress fully on track. Phase-I production blocks to be opened in mid-2027 focusing on High Potent and General OSD capability
- Filings update: DMF filings - Cumulatively, 92 filed till date. Developed market FDF filings - 2 dossiers filed and no approvals received in 1Q. Cumulatively, 96 products filed till date

LAURUS Labs
Chemistry for Better Living

Advanced Biologics – Key Updates

Gene Therapy & Anti body Drug Conjugates (ADC)

- In-licensed two ADC assets from Aarvik Therapeutics for development and commercialization for India markets
- PD team more than doubled in last 6 months & continue to grow
- Manufacturing facility build up on track with focus on Integrated offering (PD, bioconjugation and finished ADCs capabilities)
- Gram to Multi-Kg scale to support clinical & commercial supplies

Cell Therapy

- Continued uptake in volumes >660 infusions as on Jun 2026
- 2nd GMP production facility in Navi Mumbai operationalized in March 2026, with capacity to produce +2,500 treatment
- BCMA Ph-1 trails ongoing for r/r Multiple Myeloma
- Cipla partnership for South Africa market progressing well

ImmunoACT presenting CAR-T cell therapy platform at Bharat Innovates 2026, France

Strategic priorities

- Accelerate NexCar19 clinical adoption
- Portfolio expansion
- Global partnerships & Licensing opportunities

LAURUS Labs
Chemistry for Better Living

Highest standard of Quality & Compliance - Commitment to “One Quality for all Markets”

54 Successful Inspections by major Regulators (US FDA, WHO, EU EMA, and Japan PMDA)

1425+ Quality audits & Inspection by Global Customers, Regulators since inception

Q1 FY27 update

- 24 Quality audit in Q1: Regulatory # 1 & Customer # 23
- On-going improvement in QMS and implementation across different functions, incl. R&D, Quality and Technical operations
- On going digitization. LIMS implemented Unit-04 and is planned for rollout across additional sites

FDA Last US FDA inspection

Key Facilities	Key Regulatory Certifications	Date	# audits (since inception)	EIR Status
Kilo Lab – R&D	USFDA, TGA, KFDA, PMDA, ANVISA - Brazil	2024	5	✓
Unit 1	USFDA, TGA, MHRA, WHO-Geneva, PMDA, ANVISA	2024	7	✓
Unit 2	USFDA, WHO-Geneva, EMA	2023	5	✓
Unit 3	USFDA, WHO-Geneva, JAZMP-Slovenia, ANVISA	2024	5	✓
Unit 4	WHO-Geneva, USFDA	2025	2	✓
Unit 5	USFDA	2022	1	✓
Unit 6	USFDA	2018	1	✓

LAURUS Labs
Chemistry for Better Living

Earnings call details

Laurus Labs Results Conference Call to be held on Friday, 24 July 2026 at 5:00 PM IST

Dial – In – Details	
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 1012045
Hong Kong	+800 964448
USA	+1 866 746 2133
UK	+0808 101 1573

Click below to Express Join with Diamond Pass

Click here to register

LAURUS Labs
Chemistry for Better Living

Additional Information

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions. The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence.
Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices. Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

Investor relations

Vivek Kumar

T: +914066594366
E: investorrelations@lauruslabs.com
E: vivek.k@lauruslabs.com

For more information
Please visit our website www.lauruslabs.com

LAURUS Labs
Chemistry for Better Living

Please consider the environment before printing this Presentation